Context: This is one example of the dire threat posed by all AMR, one that could be killing up to 162,044 people in the U.S. every year — which would make it the third leading cause of death, says Frank. (The CDC is updating its AMR report this fall, but its last report from 2013 shows annual U.S. deaths were “at least 23,000 people.”)

• AMR is growing for multiple reasons, including a lack of return on investment.
• Frank points to Achaogen, which had received approval of an important new antibiotic targeting a superbug, but recently had to declare bankruptcy after it only made $1 million in its first 6 months on the market.

What’s next: Frank, who also is the director of infectious disease policy at the Biotechnology Innovation Organization, says the new coalition was formed to raise public awareness of the growing threat from AMR.

• The coalition also advocates for policies promoting the development of new antibiotics under a stewardship program to ensure appropriate use — and is watching bills recently introduced to the Senate: the DISARM Act and the STAAR Act.

More from Axios here.